Peptide research profile
Tesamorelin
Also known as Egrifta SV · Egrifta WR · tesa · tesaipa · TH9507
Randomized trials found reductions in visceral adipose tissue in the labeled population. The effect should not be generalized to routine weight loss, bodybuilding, or healthy aging.
High evidenceFDA approved
- Evidence maturity
- Established record
- Regulatory status
- FDA approved
- Recorded outcomes
- 3
- Indexed sources
- 3
- Side-effect records
- 71Named most often: Allergic reaction · Rash · anxiety
Educational. Not medical advice.
Summary
A growth-hormone-releasing hormone analog approved for excess abdominal fat in adults with HIV-associated lipodystrophy.
What is Tesamorelin being studied for?
HIV-associated lipodystrophy
How is it thought to work?
Stimulates pituitary growth-hormone release and downstream IGF-1 through the GHRH receptor.
Recorded outcomes
71 side-effect records on Tesamorelin
Free account3 graded outcomes and 3 sources for Tesamorelin.
Outcome table and every source open with a free account. No card.
Update history
Updated
- Editorial review of the profile and its sources.
- Record last updated in the Senzu database.
- Profile first published.